Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.56 |
| ▸ | MAOB | P27338 | 6/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.52 |
| ▸ | HTR3A | P46098 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31718484 | 0.92 | MAOA (0.61) | MAOAMAOBSLC6A4PDE3BPDE3A | |
| SCHEMBL14124586 | 0.90 | MAOA (0.60) | MAOAMAOBPDE3BPDE3ABRD4 | |
| SCHEMBL14124583 | 0.88 | MAOA (0.65) | MAOAMAOBPDE3BPDE3ABRD4 | |
| SCHEMBL12599797 | 0.87 | MAOA (0.59) | MAOAMAOBSLC6A4KCNH2PDE3B | |
| SCHEMBL31722015 | 0.82 | MAOB (0.56) | MAOAMAOBSLC6A4PDE3BPDE3A | |
| SCHEMBL15545569 | 0.80 | MAOA (0.50) | MAOAMAOBHRH3PDE3BPDE3A | |
| SCHEMBL29207445 | 0.79 | MAOA (0.59) | MAOAMAOBSLC6A4PDE3BPDE3A | |
| SCHEMBL3634904 | 0.79 | MAOA (0.59) | MAOAMAOBSLC6A4PDE3BPDE3A | |
| SCHEMBL3634905 | 0.79 | MAOA (0.59) | MAOAMAOBSLC6A4PDE3BPDE3A | |
| SCHEMBL6583075 | 0.77 | MAOB (0.67) | MAOAMAOBSLC6A4PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148432-A1 | Compounds for the Treatment of Neurological Disorders | BABU RUPPA POORNACHARY KAMALESH (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148432-A1 | Compounds for the Treatment of Neurological Disorders | BABU RUPPA POORNACHARY KAMALESH (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148432-A1 | Compounds for the Treatment of Neurological Disorders | BABU RUPPA POORNACHARY KAMALESH (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680279-B2 | Compounds for the treatment of neurological disorders | NEUROP, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680279-B2 | Compounds for the treatment of neurological disorders | NEUROP, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680279-B2 | Compounds for the treatment of neurological disorders | NEUROP, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120302543-A1 | Compounds for the Treatment of Neurological Disorders | NEUROP, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302543-A1 | Compounds for the Treatment of Neurological Disorders | NEUROP, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302543-A1 | Compounds for the Treatment of Neurological Disorders | NEUROP, INC. | 2012-11-29 | — | — | US | disclosed |
| EP-2512241-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGIC DISORDERS | Neurop, Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011075537-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGIC DISORDERS | NEUROP, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011075537-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGIC DISORDERS | NEUROP, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302543-A1 | Compounds for the Treatment of Neurological Disorders | GRIN2A, GRIN2B, GRIN2C | MAOA 180/4885MAOB 144/4885SLC6A2 377/4885 |
| US-20140148432-A1 | Compounds for the Treatment of Neurological Disorders | NR2C2, GRIN2C, CNR1 | MAOA 900/4885MAOB 1028/4885SLC6A2 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.